clinical trial · NCT01602822
Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV
Kenneth H. Mayer, MD·phase4·terminated·n = 11
HIVTenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
brief summary
This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
started
Feb 1, 2012
primary completion
May 1, 2012
completion
May 1, 2012
last updated
Jul 10, 2025
detailed description
Participants are given a regimen containing tenofovir disoproxil fumarate (TDF) 300mg and emtricitabine (FTC) 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily,for 28 days.
official title
A Phase IV Open-label Evaluation of Safety, Tolerability and Patient Acceptance of Atazanavir Boosted With Ritonavir Combined With a Fixed-dose Formulation of Tenofovir DF and Emtricitabine for nPEP Following Potential Exposure to HIV-1
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol